ArticleMikrochimica acta2026
Ternary MOF-PEDOT: PSS/AuNPs nanocomposite for ultrasensitive electrochemical detection of extracellular vesicles.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
A highly sensitive label-free aptamer-based electrochemical biosensor is reported for the direct detection of extracellular vesicles (EVs), a promising circulating biomarker associated with disease progression and intercellular communication. The sensing platform was fabricated by modifying a glassy carbon electrode (GCE) with a ternary nanocomposite comprising a metal-organic framework (MOF), poly(3,4-ethylenedioxythiophene)-poly(styrenesulfonate) (PEDOT: PSS) conductive polymer, and gold nanoparticles (AuNPs), followed by immobilization of a CD63 aptamer for selective EV recognition. Comprehensive characterization using FESEM, EDX, TEM, FT-IR, XRD, and XPS analyses confirmed the morphological, structural, and chemical properties of the nanocomposite. The synergistic integration of the high surface area and abundant binding sites of the MOF, the mixed ionic-electronic conductivity of PEDOT: PSS, and the excellent bioconjugation capability of AuNPs enhanced the electrochemical sensing performance. Under optimized conditions, the biosensor achieved an ultralow limit of detection of 3.2 particles/µL, outperforming recently reported EV biosensors, with recovery rates ranging from 87 to 100% in serum samples. Importantly, the high sensitivity of the biosensor enables reliable detection of low-abundance tumor-derived EVs in complex biological matrices (as low as ~ 10 particles/µL) while also demonstrating good reproducibility, selectivity, and storage stability. Furthermore, the platform successfully differentiated EV profiles between healthy individuals and cancer patients, highlighting its promising potential for clinical translation as a rapid and minimally invasive cancer screening tool.
Indexed as
Identifiers
42611334What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.